Active Biotech AB (DE:BTPC)
FRANKFURT:BTPC
Want to see DE:BTPC full AI Analyst Report?
BTPC Stock Chart & Stats
€0.01
<€0.01(14.29%)
At close: 4:00 PM EST
€0.01
<€0.01(14.29%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.02
Previous CloseN/A
Volume20.00K
Average Volume (3M)7.13K
Market Cap
€14.74M
Enterprise Value€14.30M
Total Cash (Recent Filing)€65.10M
Total Debt (Recent Filing)€260.00K
Price to Earnings (P/E)―
Beta-6.53
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding2,636,067,100
10 Day Avg. Volume2,383
30 Day Avg. Volume7,129
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.11
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageThe company reports debt at zero in 2025 and very low leverage. This durable balance sheet position reduces solvency and interest risks, gives management flexibility to finance R&D via equity or partnerships, and preserves strategic optionality over the next several quarters.
Improving Cash Burn And Operating LossesOperating losses and cash burn have narrowed versus 2022–2023 (EBIT improved materially). If this trend persists it lengthens runway, lowers near-term financing needs, and improves the company’s ability to advance programs without immediate large capital raises.
Focused R&D In High-demand Therapeutic AreasA concentrated focus on immune-modulating small molecules for autoimmune, inflammatory diseases and oncology aligns with strong, structural demand and partner interest. This specialization supports deep scientific expertise and enhances licensing or collaboration potential over the medium term.
Bears Say
No RevenueThe company generated no revenue from 2021–2025, meaning it has no commercial cash flow base. Long-term viability depends on clinical success, licensing or landmark partnerships; absent product revenue this raises sustained funding and execution risk.
Persistent Negative Operating Cash FlowOperating cash flow is materially negative year-after-year, driving ongoing cash burn. Persistent outflows increase reliance on external financing, heighten dilution risk for shareholders, and constrain the company's ability to scale programs or invest in parallel development projects.
Sustained Net Losses And Weak ROENet losses persist and return on equity is deeply negative, eroding shareholder value and making equity levels volatile. Continued unprofitability forces strategic dependence on dilutive capital raises or large partnerships to sustain operations over the medium term.
Active Biotech AB News
BTPC FAQ
What was Active Biotech AB’s price range in the past 12 months?
Active Biotech AB lowest stock price was <€0.01 and its highest was €0.02 in the past 12 months.
What is Active Biotech AB’s market cap?
Active Biotech AB’s market cap is €14.74M.
When is Active Biotech AB’s upcoming earnings report date?
Active Biotech AB’s upcoming earnings report date is May 07, 2026 which is in 6 days.
How were Active Biotech AB’s earnings last quarter?
Active Biotech AB released its earnings results on Feb 12, 2026. The company reported >-€0.001 earnings per share for the quarter, missing the consensus estimate of N/A by >-€0.001.
Is Active Biotech AB overvalued?
According to Wall Street analysts Active Biotech AB’s price is currently Overvalued.
Does Active Biotech AB pay dividends?
Active Biotech AB does not currently pay dividends.
What is Active Biotech AB’s EPS estimate?
Active Biotech AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Active Biotech AB have?
Active Biotech AB has 2,636,067,100 shares outstanding.
What happened to Active Biotech AB’s price movement after its last earnings report?
Active Biotech AB reported an EPS of >-€0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -9.091%.
Which hedge fund is a major shareholder of Active Biotech AB?
Currently, no hedge funds are holding shares in DE:BTPC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Active Biotech AB
Active Biotech AB (publ), a biotechnology company, develops pharmaceutical products the treatment of oncology and immunology diseases in Sweden. It is developing Tasquinimod, a small molecule immuno-modulator, which is in Phase Ib/IIa clinical trial to treat multiple myeloma; Laquinimod, an immunomodulator that is in phase I clinical trial for the treatment of inflammatory eye disorders, including uveitis; and Naptumomab, an anti-cancer immunotherapy, which is in phase Ib/II clinical trial to treat patients with advanced solid tumors. The company has a licensing agreement with NeoTX Therapeutics Ltd. for the development and commercialization of Naptumomab for cancer immunotherapy. Active Biotech AB (publ) was incorporated in 1983 and is headquartered in Lund, Sweden.
Technical Analysis
Medivir AB
―
Isofol Medical AB
―
Xintela AB
―
Elicera Therapeutics AB
―
IRLAB Therapeutics AB Class A
―